CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU...
Phase 3
Birmingham, Alabama, United States and 5 other locations
designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...
Phase 2
Birmingham, Alabama, United States and 39 other locations
efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...
Phase 2, Phase 3
Birmingham, Alabama, United States and 37 other locations
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...
Phase 2, Phase 3
Birmingham, Alabama, United States and 37 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
Birmingham, Alabama, United States and 117 other locations
be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...
Phase 2
Birmingham, Alabama, United States and 168 other locations
compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD).Stage 2 will evaluate the effect of earl...
Phase 2, Phase 3
Birmingham, Alabama, United States and 34 other locations
investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determ...
Phase 2, Phase 3
Birmingham, Alabama, United States and 34 other locations
outpatient study in subjects with psychosis associated with Alzheimer's Disease.The primary objective of the study is to evaluate r ...
Phase 3
Homewood, Alabama, United States and 106 other locations
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's...
Phase 2
Birmingham, Alabama, United States and 122 other locations
Clinical trials
Research sites
Resources
Legal